Lecture Details - Overview
Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics
Release Date: February 27, 2009|
Expiration Date: February 27, 2010
Dec 10, 2008, San Antonio, TX
Lecture Overview
The role of targeted biologic agents in the treatment of breast cancer is rapidly expanding and evolving. The armamentarium of agents in use or under investigation for HER2+ breast cancer is growing, and many of these new compounds have demonstrated efficacy even in patients who have progressed on prior HER2-targeted therapy. Investigation into mechanisms of resistance to conventional therapy has uncovered a number of potential targets, such as members of the PI3K/Akt pathway, and mammalian target of rapamycin (mTOR) inhibitors are in active clinical development. Angiogenic pathways are also the target of clinical investigation. Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics is an educational activity designed to update medical oncologists on recent clinical trial data that might impact physician practice. The purpose of this program is to discuss strategies for integrating novel targeted agents into treatment regimens for patients with metastatic breast cancer (MBC), including as monotherapy or in combination with endocrine therapy, chemotherapy, or other biologic agents. The relevance of data reported at recent international oncology conferences to physician practice will also be discussed.
The purpose of this activity is to update physicians on the latest clinical data on the use of HER2-targeted agents and other novel signal transduction inhibitors in the treatment of patients with MBC.
This on-demand Webcast is from an event held in conjunction with the 31st Annual San Antonio Breast Cancer Symposium held on December 10-14, 2008, in San Antonio, TX.
This educational program is directed toward medical oncologists interested in reviewing the most recent clinical trial data on the treatment of breast cancer. Surgical and radiation oncologists, physician assistants, and other health care professionals interested in the treatment of breast cancer are also invited to participate.
Upon completion of this educational activity, you should be able to:
- Evaluate the utility of novel antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 for the treatment of HER2+ MBC
- Review the efficacy and safety of mTOR inhibitors in combination regimens for the treatment of advanced/metastatic breast cancer
Accreditation and Credit Designation
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View and study all Flash video presentations.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
- You will be permitted 2 attempts to successfully complete the Posttest.
You will be asked to login
or create an account.